GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx預測第二季度收入約爲2億美元，而市場預期爲1.9957億美元，調整後的息稅折舊攤銷前利潤率處於低的30％區間
GoodRx Forecasts Q2 Revenue Of ~$200M Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx預測第二季度收入約爲2億美元，而市場預期爲1.9957億美元，調整後的息稅折舊攤銷前利潤率處於低的30％區間
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。